MYNZ: 8-K · material agreement
Quantum Cyber N.V. (QUCY) announced the termination of its at-the-market equity sales agreement with Maxim Group LLC, effective June 7, 2026. The company successfully sold 3,280,927 ordinary shares under the agreement, generating net proceeds of approximately $4.4 million. No termination penalties were incurred, and the filing serves as a formal closure of this specific capital raising channel.
MYNZ: S-3 · shelf registration
Quantum Cyber N.V. has filed a shelf registration statement on Form S-3, permitting the company to offer up to $250 million of ordinary shares, preferred shares, warrants, subscription rights, and units from time to time. The securities may be sold in one or more offerings, with the specific terms, prices, and agents to be detailed in future prospectus supplements. Proceeds from any future sales are intended for general corporate purposes, including working capital and capital expenditures. As of May 21, 2026, the company reported approximately 22.8 million ordinary shares outstanding, with a public float of roughly $78.5 million calculated at a share price of $3.56. The company recently rebranded from Mainz Biomed N.V. to Quantum Cyber N.V. in April 2026 and operates through its U.S. subsidiary, Quantum Drones Corporation, focusing on AI and quantum computing platforms for autonomous vehicles.
Quantum Cyber N.V. (QUCY) amended its Intellectual Property License Agreement with BP United Inc. to eliminate a $5 million cash payment obligation. Instead, QUCY will retain the funds to finance the ramp-up of its own manufacturing operations for licensed defense products, while BP United provides technical assistance and consulting services. The amendment removes the requirement for an Exclusive Supply Agreement, allowing QUCY to control manufacturing directly. Consideration shares issued to BP United and advisors will now vest in four equal quarterly installments starting September 30, 2026, and are subject to forfeiture if the agreement is terminated early. The filing includes a corporate presentation highlighting QUCY’s tri-domain autonomous defense platforms (SWARM-X, FALCON 55, GUARDIAN-X) and letters of intent with General Cherry and SOCOM. The company emphasizes its vertically integrated US manufacturing strategy and clean capital structure with 22.7 million shares outstanding and zero debt.
MYNZ: DEF 14A · proxy statement
Quantum Cyber N.V. is soliciting shareholder approval for a radical strategic pivot from molecular genetic diagnostics to quantum computing and autonomous defense technologies. The proxy statement seeks to amend the company’s Articles of Association to authorize activities in drone warfare, counter-unmanned aircraft systems, and post-quantum cryptography, reflecting a complete departure from its original business model. The filing discloses a $6 million private placement of preferred shares to CEO David Lazar, who is also the company’s largest shareholder. This transaction involves the issuance of Series A through E Preferred Shares, which are convertible into up to 459 million ordinary shares. This potential dilution exceeds 20 times the current 22.7 million ordinary shares outstanding, creating extreme downside risk for existing shareholders if the preferred shares convert. Governance concerns are heightened by related-party transactions and significant executive compensation changes. The board proposes increasing non-executive director fixed remuneration from $50,000 to $100,000 annually and expanding the annual share award pool for the board from 500,000 to 10 million shares. Additionally, settlement agreements with the CEO and CFO totaling over $1.7 million are contingent on the approval of these proposals, aligning management’s financial interests with the passage of the dilutive capital raise.
MYNZ: 8-K · other
Quantum Cyber N.V. announced it has regained compliance with Nasdaq listing rules after its stock price closed at or above $1.00 for 10 consecutive business days. This resolves a delisting warning issued in March 2026 when the company failed to maintain the minimum bid price for 30 days. The Nasdaq Listing Qualifications Department confirmed the matter is now closed, removing the immediate threat of delisting from the Nasdaq Capital Market. While this is a positive development for listing status, it reflects a short-term price recovery rather than a fundamental change in the company's business operations or financial health.
MYNZ: 8-K · offering registration
Quantum Cyber N.V. (QUCY) announced that warrant holders have fully exercised outstanding warrants, generating approximately $15 million in gross proceeds. The company confirmed that these funds have been received and are held on its balance sheet, allowing it to retire all outstanding debt obligations and achieve a debt-free capital structure. The filing discloses that the company now has 22,767,254 ordinary shares outstanding and no remaining exercisable warrants. Management intends to deploy the net proceeds toward expanding research and development, building out its commercialization team, and executing its strategic acquisition pipeline, including finalizing existing deals in autonomous defense technologies. The company also highlighted its strategic focus on AI-powered autonomous systems for drone warfare, counter-UAS, and border security, aligning with U.S. Department of Defense budget priorities. Despite the capital raise, the company remains subject to a Nasdaq compliance period regarding its minimum bid price requirement, with a deadline of September 16, 2026, to regain compliance or face potential delisting.
Quantum Cyber N.V. (QUCY) entered into an Intellectual Property License Agreement with BP United Inc. on May 12, 2026, granting the company an exclusive, perpetual, and fully paid-up worldwide license to certain technology applicable to drones and cyber applications. The consideration for this license is $5 million in cash and 20 million restricted shares of QUCY common stock, subject to satisfaction of conditions precedent including IP due diligence and corrective patent filings within 90 days. Concurrently, QUCY engaged Alexander Gurevich as an independent advisor under a 12-month agreement, compensating him with 5 million restricted shares valued at $0.40 per share. This brings the total potential dilution from these transactions to 25 million shares, representing a significant increase in the company's share count if the conditions are met. In a separate Item 5.02 disclosure, the Board appointed Peter O’Rourke as a director effective May 13, 2026, to fill a vacancy. O’Rourke brings experience from TCI Partners, Western Magnesium Corporation, and previous board roles at NorthView Acquisition Corporation and ProFusa, Inc.
MYNZ: 10-Q · periodic report
Quantum Cyber N.V. (formerly Mainz Biomed) reported a net loss of $5.1 million for Q1 2026, citing a material weakness in internal controls and raising substantial doubt about its ability to continue as a going concern due to an accumulated deficit of $110 million. The company executed a strategic pivot, exiting its colorectal cancer business by selling the ColoAlert and NextGen intellectual property for approximately $1.6 million in total proceeds, while terminating all employees in its German subsidiary. To fund operations and its new focus on pancreatic cancer screening and post-quantum cybersecurity, the company raised $8.1 million through the issuance of preferred and ordinary shares, and entered into a license agreement with BP United Inc. for cyber and drone technology. In subsequent events, the company changed its name to Quantum Cyber N.V., adopted the ticker QUCY, appointed David Lazar as CEO, and authorized a potential reverse stock split to maintain Nasdaq listing compliance.
